Details of the Drug

General Information of Drug (ID: DM13P4C)

Drug Name
Salsalate
Synonyms
Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Therapeutic Class
Antiinflammatory Agents
Affected Organisms
Humans and other mammals
ATC Code
N02BA06: Salsalate
N02BA: Salicylic acid and derivatives
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 258.23
Logarithm of the Partition Coefficient (xlogp) 3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour (parent compound), and 3.5 - 16 hours (active metabolite) [3]
Chemical Identifiers
Formula
C14H10O5
IUPAC Name
2-(2-hydroxybenzoyl)oxybenzoic acid
Canonical SMILES
C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
InChI
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
InChIKey
WVYADZUPLLSGPU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5161
ChEBI ID
CHEBI:9014
CAS Number
552-94-3
UNII
V9MO595C9I
DrugBank ID
DB01399
TTD ID
D0Y0JH
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Salsalate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Salsalate caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [5]
Tromethamine DMOBLGK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [6]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Salsalate and Inotersen. Amyloidosis [5D00] [7]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Salsalate and ABT-492. Bacterial infection [1A00-1C4Z] [8]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Salsalate and Iodipamide. Cholelithiasis [DC11] [9]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Salsalate and Ardeparin. Coronary thrombosis [BA43] [10]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Salsalate and Danaparoid. Deep vein thrombosis [BD71] [10]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Salsalate and Rivaroxaban. Deep vein thrombosis [BD71] [10]
SODIUM CITRATE DMHPD2Y Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [6]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Salsalate due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [11]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Salsalate and Teriflunomide. Hyper-lipoproteinaemia [5C80] [12]
Sodium acetate anhydrous DMH21E0 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [6]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Salsalate and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [13]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Salsalate and Exjade. Mineral absorption/transport disorder [5C64] [14]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Salsalate and Deflazacort. Muscular dystrophy [8C70] [15]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Salsalate and Prasugrel. Myocardial infarction [BA41-BA43] [16]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Salsalate and Everolimus. Renal cell carcinoma [2C90] [17]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Salsalate and Temsirolimus. Renal cell carcinoma [2C90] [17]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Salsalate and Apixaban. Thrombosis [DB61-GB90] [10]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Salsalate and Brilinta. Thrombosis [DB61-GB90] [7]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Salsalate and Insulin degludec. Type-1/2 diabete [5A10-5A11] [18]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Salsalate and Plazomicin. Urinary tract infection [GC08] [19]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Salsalate and Betrixaban. Venous thromboembolism [BD72] [10]
⏷ Show the Full List of 23 DDI Information of This Drug

References

1 Comparative Effectiveness and Safety of Analgesics for Osteoarthritis. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Sep. Report No.: 06-EHC009-EF.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Balali-Mood M, Prescott LF "Failure of alkaline diuresis to enhance diflunisal elimination." Br J Clin Pharmacol 10 (1980): 163-5. [PMID: 7426277]
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
9 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
10 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
11 Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
12 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
13 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
14 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
15 Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
16 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
17 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
18 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
19 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]